Clinical Studies

If you are interested in learning more about our ongoing clinical studies, please contact us at ClinicalStudiesInfo@atarabio.com.

Phase Trial Number Trial Description
Atara tab-cel™ (tabelecleucel; formerly called Atara ATA129) 3 NCT03392142 Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With EBV+ PTLD After Failure of Rituximab (MATCH)
3 NCT03394365 Tabelecleucel for Solid Organ Transplant Subjects With EBV+ PTLD After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)
2 NCT01498484 Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From A Normal HLA- Compatible Or Partially- Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies
1/2 NCT00002663 Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
Atara ATA188 1 NCT03283826 Phase 1 Study to Evaluate the Safety of ATA188 in Subjects With Progressive and Relapsing-Remitting Multiple Sclerosis
Atara ATA230 2 NCT02136797 Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
2 NCT01646645 Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
Atara ATA520 1 NCT00620633 Dose Escalation Trial of WT1-Sensitized T-Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation
1 NCT01758328 Dose Escalation Trial of WT1-specific Donor-derived T cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma